Kyowa Hakko Kirin Co., Limited

Fujifilm Corporation

Kyowa Hakko Kogyo Co., Ltd.

Fuji Photo Film Company, Limited

Ryuichiro Nakai

Yoshinori Yamashita

Chikara Murakata

Takeshi Takahashi

Yoshihisa Ohta

Kazuhiko Kato

Shiro Akinaga

Tamio Mizukami

Yuichi Takahashi

Akira Asai

Katsuhiko Ando

Shigeru Chiba

Yuichi Fukuda

Nobuyoshi Amishiro

Hideaki Kusaka

Tsutomu Agatsuma

Kozo Ouchi

Hideki Kawasaki

Junichiro Yamamoto

Yushi Kitamura

Harumi Ogawa

Shingo Kakita

Hisashi Tagaya

Hiroshi Ishida

Keiichi Motosawa

Toshiyuki Atsumi

Hiroko Takahashi

Jun Funahashi

Emi Shimoike

Ryoko Okada

Yusuke Miura

Yoji Ino

A Wnt signaling inhibitor which comprises, as an active ingredient, a fused-ring heterocyclic compound represented by the following formula (IA) or a pharmaceutically acceptable salt thereof, and the like are provided: (wherein, nrepresents 0 or 1; nand nmay be the same or different, and each represents 1 or 2; Rrepresents optionally substituted aryl or the like; Rrepresents a hydrogen atom or the like; Rrepresents an optionally substituted aromatic heterocyclic group or the like; X, X, Xand Xeach represent CH or the like; Yrepresents CHor the like; Yrepresents N or the like; and Lrepresents CHor the like).

Wnt signaling inhibitor

A therapeutic and/or prophylactic agent for restenosis, which comprises a thiadiazoline derivative represented by the general formula (0), or a pharmaceutically acceptable salt thereof: [wherein, n represents an integer of 1 to 3, Rrepresents aryl, &#x2014;NRCONR(wherein Rrepresents a hydrogen atom or the like, and Rrepresents lower alkyl or the like) or the like, Rrepresents lower alkyl, Rrepresents a hydrogen atom or the like, and Rrepresents aryl or the like].

Therapeutic agent for restenosis

(wherein Rand Rare the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; Rrepresents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; Rrepresents &#x2014;C(&#x2550;W)Ror the like; Rrepresents a hydrogen atom, &#x2014;C(&#x2550;W)R, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided. 

Thiadiazoline derivative

(wherein Rand Rare the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; Rrepresents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; Rrepresents &#x2014;C(&#x2550;W)Ror the like; Rrepresents a hydrogen atom, &#x2014;C(&#x2550;W)R, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.

The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I): {wherein W represents a nitrogen atom or &#x2014;CH&#x2014;; 

Nitrogen-containing heterocyclic compound

The present invention relates to chrolactomycin compound represented by the following formula (I): ##STR1## or pharmaceutically acceptable salts thereof having antibacterial and antitumor activities.

Chrolactomycin compound

UCS1025 compounds represented by the following formula (I): ##STR1## wherein R represents hydrogen or hydroxyl group, or tautomers or pharmacologically acceptable salts thereof.

UCS1025 compounds

Growing community of inventors

Shizuoka, Japan

Ryuichiro Nakai